Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.75 |
| ▸ | PGR | P06401 | 5/20 | 0.75 |
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.66 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | AR | P10275 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desonide SCHEMBL11778722 | 0.95 | CYP3A4 (0.73) | CYP3A4HIF1ANR3C1PGRLMNA | |
| Triamcinolone Acetonide SCHEMBL1561091 | 0.91 | HIF1A (0.89) | CYP3A4HIF1ANR3C1PGRLMNA | |
| Triamcinolone Acetonide SCHEMBL1446089 | 0.91 | HIF1A (0.89) | CYP3A4HIF1ANR3C1PGRLMNA | |
| Triamcinolone Acetonide SCHEMBL8780600 | 0.90 | HIF1A (0.87) | CYP3A4HIF1ANR3C1PGRLMNA | |
| Desonide SCHEMBL28086567 | 0.90 | NR3C1 (0.71) | CYP3A4HIF1ANR3C1PGRLMNA | |
| Triamcinolone Acetonide SCHEMBL9987506 | 0.88 | CYP3A4 (0.75) | CYP3A4HIF1ANR3C1PGRLMNA | |
| Flunisolide SCHEMBL20915050 | 0.87 | CYP3A4 (0.69) | CYP3A4HIF1ANR3C1PGRLMNA | |
| Triamcinolone Acetonide SCHEMBL20915153 | 0.87 | HIF1A (0.77) | CYP3A4HIF1ANR3C1PGRLMNA | |
| Fluocinolone Acetonide SCHEMBL8450831 | 0.87 | NR3C1 (0.77) | CYP3A4HIF1ANR3C1PGRLMNA | |
| Desonide SCHEMBL4457124 | 0.87 | CYP3A4 (0.63) | CYP3A4HIF1ANR3C1PGRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023275715-A1 | METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS | PFIZER INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-3148587-B1 | CARBONITRILE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS | PFIZER (US) | 2021-02-24 | — | — | EP | disclosed |
| US-10662148-B2 | Selective androgen receptor modulator and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-05-26 | — | — | US | disclosed |
| US-10328082-B2 | Methods of use and combinations | PFIZER INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20190055192-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATOR AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2019-02-21 | — | — | US | disclosed |
| US-20180273470-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATOR AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2018-09-27 | — | — | US | disclosed |
| US-10053418-B2 | Selective androgen receptor modulator and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-08-21 | — | — | US | disclosed |
| US-20180071242-A1 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2018-03-15 | — | — | US | disclosed |
| US-9889110-B2 | Selective androgen receptor modulator for treating hormone-related conditions | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-02-13 | — | — | US | disclosed |
| US-9884038-B2 | Selective androgen receptor modulator and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2018-02-06 | — | — | US | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008127717-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS FOR TREATING DIABETES | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008091555-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20080076829-A1 | Substituted acylanilides and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-03-27 | — | — | US | disclosed |
| US-20080076828-A1 | Substituted acylanilides and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-03-27 | — | — | US | disclosed |
| US-20080057068-A1 | SARMS and method of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-03-06 | — | — | US | disclosed |
| WO-2008024456-A2 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008008433-A2 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070281906-A1 | Selective androgen receptor modulators for treating diabetes | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2007-12-06 | — | — | US | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662148-B2 | Selective androgen receptor modulator and methods of use thereof | AR, MUSK, FSHR | NR3C1 18/4885CYP3A4 2305/4885HIF1A 991/4885 |
| US-20080076829-A1 | Substituted acylanilides and methods of use thereof | CPT1B, MTPN, MUSK | NR3C1 1691/4885CYP3A4 2811/4885HIF1A 600/4885 |
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | NR3C1 56/4885CYP3A4 1000/4885HIF1A 739/4885 |
| US-20180071242-A1 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | CPT1B, MTPN, MUSK | NR3C1 1709/4885CYP3A4 3550/4885HIF1A 1724/4885 |
| US-20080057068-A1 | SARMS and method of use thereof | SARM1, CKMT1A; CKMT1B, TNNI3 | NR3C1 1811/4885CYP3A4 3279/4885HIF1A 96/4885 |
| US-10328082-B2 | Methods of use and combinations | AR, MC2R, ESRRA | NR3C1 24/4885CYP3A4 636/4885HIF1A 2380/4885 |
| US-20190055192-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATOR AND METHODS OF USE THEREOF | AR, ESRRA, SHBG | NR3C1 17/4885CYP3A4 1974/4885HIF1A 813/4885 |
| US-20070281906-A1 | Selective androgen receptor modulators for treating diabetes | AR, GPR119, NR5A1 | NR3C1 121/4885CYP3A4 2387/4885HIF1A 193/4885 |
| US-20090030036-A1 | Nuclear receptor binding agents | NR0B1, NR2E3, NR0B2 | NR3C1 19/4885CYP3A4 2085/4885HIF1A 1007/4885 |
| US-20080076828-A1 | Substituted acylanilides and methods of use thereof | CPT1B, MTPN, MUSK | NR3C1 1392/4885CYP3A4 2407/4885HIF1A 1221/4885 |
| US-10053418-B2 | Selective androgen receptor modulator and methods of use thereof | AR, MUSK, FSHR | NR3C1 18/4885CYP3A4 2305/4885HIF1A 991/4885 |
| US-20180273470-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATOR AND METHODS OF USE THEREOF | AR, MUSK, FSHR | NR3C1 18/4885CYP3A4 2305/4885HIF1A 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.